Edition:
United States

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

24.57USD
22 May 2017
Change (% chg)

$0.16 (+0.66%)
Prev Close
$24.41
Open
$24.44
Day's High
$24.68
Day's Low
$24.36
Volume
37,110
Avg. Vol
61,214
52-wk High
$26.95
52-wk Low
$15.85

Latest Key Developments (Source: Significant Developments)

Quidel receives FDA clearance for Solana(R) molecular assay for detecting C. difficile infections
Thursday, 11 May 2017 02:30pm EDT 

May 11 (Reuters) - Quidel Corp ::Quidel receives FDA clearance for its new Solana(R) molecular assay for the detection of Clostridium difficile (C. difficile) infections.Received 510(k) clearance from U.S. FDA to market its Solana C. difficile Assay for detection of Clostridium difficile (C. difficile) infections.  Full Article

Quidel reports Q1 earnings per share $0.42
Monday, 24 Apr 2017 04:10pm EDT 

April 24 (Reuters) - Quidel Corp -:Quidel reports first quarter 2017 financial results.Q1 gaap earnings per share $0.42.Q1 revenue $73.7 million versus i/b/e/s view $60.8 million.Q1 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Q1 non-gaap earnings per share $0.45.  Full Article

Quidel reports Q4 gaap loss per share $0.06
Wednesday, 8 Feb 2017 04:10pm EST 

Quidel Corp : Quidel reports fourth quarter and full year 2016 financial results . Q4 GAAP loss per share $0.06 . Q4 revenue $52.8 million versus I/B/E/S view $57.5 million . Q4 earnings per share view $0.10 -- Thomson Reuters I/B/E/S .Q4 non-GAAP earnings per share $0.17.  Full Article

Quidel Corp says voluntarily terminated its $140.0 million senior secured syndicated credit facility
Friday, 2 Dec 2016 04:17pm EST 

Quidel Corp : Quidel corp - on december 1 voluntarily terminated its $140.0 million senior secured syndicated credit facility . Quidel corp - in connection with termination, company expects to incur a charge in q4 of $0.2 million .Quidel corp - from termination date to maturity date in august 2017 company anticipates cost savings of approximately $0.6 million..  Full Article

Quidel reports Q3 GAAP loss per share $0.02
Wednesday, 26 Oct 2016 04:10pm EDT 

Quidel Corp : Quidel reports third quarter 2016 financial results . Q3 non-gaap earnings per share $0.10 . Q3 gaap loss per share $0.02 . Q3 revenue $49.3 million versus i/b/e/s view $50.9 million .Q3 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.  Full Article

Quidel receives FDA clearance for Solana Influenza A+B Assay
Tuesday, 27 Sep 2016 01:14pm EDT 

Quidel Corp : Quidel receives FDA clearance for its Solana(R) Influenza A+B assay in time for the upcoming 2016-2017 flu season .Received 510(k) clearance from United States Food and Drug Administration (FDA) to market its Solana Influenza A+B assay.  Full Article

Quidel gets FDA clearance for Solana Trichomonas assay
Wednesday, 17 Aug 2016 02:00pm EDT 

Quidel Corp : Quidel receives FDA clearance for its Solana Trichomonas assay for diagnosis of trichomoniasis .Has received clearance from United States Food and Drug Administration to market its Solana Trichomonas assay.  Full Article

Quidel Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S
Wednesday, 27 Jul 2016 04:10pm EDT 

Quidel Corp : Quidel reports second quarter 2016 financial results . Q2 Non-GAAP loss per share $0.11 . Q2 GAAP loss per share $0.24 . Q2 revenue $39.1 million versus I/B/E/S view $38 million .Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Quidel receives FDA clearance for Solana(R) molecular assay for detecting C. difficile infections

* Quidel receives FDA clearance for its new Solana(R) molecular assay for the detection of Clostridium difficile (C. difficile) infections